Burning through the pain: Treatments for diabetic neuropathy

Diabetes, Obesity and Metabolism

Volumn 17, Issue 12, 2015, Pages 1115-1125

  Javed, S ^a   Alam, U ^b   Malik, Rayaz A ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Diabetes care; Diabetes complications; Diabetic neuropathy; Medicines management; Painful diabetic neuropathy

Indexed keywords

ACTOVEGIN; ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; ANALGESIC AGENT; BENFOTIAMINE; CAPSAICIN; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; EPALRESTAT; GABAPENTIN; LIDOCAINE; LIDORESTAT; NERVE GROWTH FACTOR; PLACEBO; PONALRESTAT; PREGABALIN; PROTEIN KINASE C INHIBITOR; RANIRESTAT; RUBOXISTAURIN; SORBINIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAPENTADOL; THIOCTIC ACID; TOLRESTAT; TRANDOLAPRIL; UNINDEXED DRUG; VASODILATOR AGENT; ZENARESTAT; ZOPOLRESTAT; ANTIDIABETIC AGENT;

ANALGESIA; BLOOD PRESSURE; BODY MASS; BRIEF PAIN INVENTORY; BURNING SENSATION; CONFOCAL MICROSCOPY; CONFUSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; FATIGUE; GLYCEMIC CONTROL; HUMAN; HYPERHIDROSIS; INSULIN DEPENDENT DIABETES MELLITUS; MCGILL PAIN QUESTIONNAIRE; NAUSEA; NEUROPATHIC PAIN QUESTIONNAIRE; NEUROPATHIC PAIN SYMPTOMS INVENTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PANCREAS TRANSPLANTATION; PERIPHERAL EDEMA; PREVALENCE; QUESTIONNAIRE; REVIEW; SEDATION; SENSORY NERVE CONDUCTION; SIDE EFFECT; SKIN BIOPSY; SKIN IRRITATION; SMOKING; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; XEROSTOMIA; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIFFERENTIAL DIAGNOSIS; MULTIMODALITY CANCER THERAPY; NEURALGIA; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE;

ANALGESICS; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; NEURALGIA; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE;

EID: 84945481606     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12535     Document Type: Review

References (98)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. IDF. IDF Diabetes Atlas. 6th edn. Brussels, Belgium 2013.
3. Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care 2008; 31: 624-625.
4. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
5. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009; 32: 2225-2229.
6. Oliveira AF, Valente JG, Leite Ida C, Schramm JM, Azevedo AS, Gadelha AM. Global burden of disease attributable to diabetes mellitus in Brazil. Cad Saude Publica 2009; 25: 1234-1244.
7. Tesfaye S, Boulton AJM, Dyck PJ etal. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.
8. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220-2224.
9. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther 2013; 35: 612-623.
10. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374-385.
11. Tavakoli M, Petropoulos IN, Malik RA. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. J Diabetes Sci Technol 2013; 7: 1179-1189.
12. Vileikyte L, Peyrot M, Bundy C etal. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003; 26: 2549-2555.
13. Dyck PJ, Kratz KM, Karnes JL etal. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
14. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36: 2456-2465.
15. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002; 6(Suppl. A): 51-60.
16. Tesfaye S, Vileikyte L, Rayman G etal. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011; 27: 629-638.
17. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990; 39: 898-908.
18. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-360.
19. Boulton AJM, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy. Diabetes Metab Res Rev 2013; 29: 327-33.
20. Boulton AJ, Vinik AI, Arezzo JC etal. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
21. Malik RA. Why are there no good treatments for diabetic neuropathy? Lancet Diabetes Endocrinol 2014; 2: 607-609.
22. Tesfaye S, Stevens LK, Stephenson JM etal. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-1384.
23. Tesfaye S, Chaturvedi N, Eaton SEM etal. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
24. Pop-Busui R, Herman WH, Feldman EL etal. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10: 276-282.
25. Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 31-38.
26. Stratton IM, Adler AI, Neil HAW etal. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
27. Ohkubo Y, Kishikawa H, Araki E etal. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
28. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M etal. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
29. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; (6): CD007543.
30. Agudo R, Valls-Solé J, Recasens M, Fabregat N, Ricart MJ, Esmatjes E. Effects of kidney and pancreas transplantation on neurophysiological rates of polyneuropathy and autonomous cardiac function in diabetic patients with end-stage renal disease. Med Clin (Barc) 2002; 118: 534-538.
31. Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 1031-1037.
32. Tavakoli M, Mitu-Pretorian M, Petropoulos IN etal. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes 2013; 62: 254-60.
33. Del Carro U, Fiorina P, Amadio S etal. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007; 30: 3063-3069.
34. Dyck PJ, Norell JE, Tritschler H etal. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007; 30: 2619-2625.
35. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521-534.
36. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007: 4CD004572.
37. Hammes HP, Du X, Edelstein D etal. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
38. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116: 600-605.
39. Malik RA, Williamson S, Abbott C etal. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
40. Ruggenenti P, Lauria G, Iliev IP etal. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011; 58: 776-783.
41. Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J 2013; 37: 375-384.
42. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 2445-2464.
43. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003; 52: 536-541.
44. Ekberg K, Brismar T, Johansson BL etal. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007; 30: 71-76.
45. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32: 1479-1484.
46. Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 2013; 29: 327-333.
47. Azmi S, Ferdousi M, Petropoulos IN etal. Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection. Diabetes Care 2015; 38: e3-4.
48. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58: 1634-1640.
49. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15: 113-119.
50. Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep 2012; 12: 403-413.
51. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-158.
52. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007; 11: 652-664.
53. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007; 67: 569-585.
54. Rudroju N, Bansal D, Talakokkula ST etal. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician 2013; 16: E705-714.
55. Max MB, Kishore-Kumar R, Schafer SC etal. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9; discussion 1-2.
56. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
57. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009; 7: 331-336.
58. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; (1): CD007115.
59. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-118.
60. Wernicke JF, Wang F, Pritchett YL etal. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007; 8: 503-513.
61. Griebeler ML, Morey-Vargas OL, Brito JP etal. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med 2014; 161: 639-649.
62. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014; 14: 167-184.
63. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005; 9: 543-554.
64. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand 2006; 113: 395-404.
65. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006; 114: 177-180.
66. Backonja M, Beydoun A, Edwards KR etal. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836.
67. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 2001; 17: 284-295.
68. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; (4): CD007938.
69. Boyle J, Eriksson MEV, Gribble L etal. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35: 2451-2458.
70. Sicras A, Rejas J, Navarro R, Planas A. Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis. Clin Drug Investig 2013; 33: 825-835.
71. Raskin P, Donofrio PD, Rosenthal NR etal. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63: 865-873.
72. Donofrio PD, Raskin P, Rosenthal NR etal. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther 2005; 27: 1420-1431.
73. Thienel U, Neto W, Schwabe SK, Vijapurkar U, Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004; 110: 221-231.
74. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013; (12): CD006044.
75. Harati Y, Gooch C, Swenson M etal. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
76. Schwartz S, Etropolski M, Shapiro DY etal. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27: 151-162.
77. Christoph T, Schröder W, Tallarida RJ, De Vry J, Tzschentke TM. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 2013; 347: 794-801.
78. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
79. Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care 2011; 38: 71-90, vi.
80. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991; 151: 2225-2229.
81. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004; 127: 1606-1615.
82. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002; 25: 1699-1703.
83. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-918.
84. Yuan RY, Sheu JJ, Yu JM etal. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72: 1473-1478.
85. Thakral G, Kim PJ, LaFontaine J, Menzies R, Najafi B, Lavery LA. Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol 2013; 7: 1202-1209.
86. Garrow AP, Xing M, Vere J, Verrall B, Wang L, Jude EB. Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupunct Med 2014; 32: 242-249.
87. Chen W, Yang GY, Liu B, Manheimer E, Liu JP. Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PLoS One 2013; 8: e73764.
88. Singleton JR, Marcus RL, Jackson JE, Lessard MK, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol 2014; 1: 844-849.
89. Singleton JR, Marcus RL, Lessard MK, Jackson JE, Smith AG. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol 2015; 77: 146-153.
90. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252-1261.
91. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-1334.
92. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009; 26: 1019-1026.
93. Tesfaye S, Wilhelm S, Lledo A etal. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"-a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154: 2616-2625.
94. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-583.
95. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013; 716: 61-76.
96. Bhatt LK, Veeranjaneyulu A. Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy. Neurol Sci 2010; 31: 705-716.
97. Rice AS, Dworkin RH, McCarthy TD etal. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014; 383: 1637-1647.
98. Brines M, Dunne AN, Van Velzen M etal. ARA 290, a non-erythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015; 20: 658-666.